Merck ends COVID-19 vaccine program, cites inferior immune responses
Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
Strong sales of drugs, vaccines, propel Merck in third quarter
The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.
Merck Covid-19 vaccine begins human testing
The Wall Street Journal is reporting that Merck & Co. has begun testing one of its experimental Covid-19 vaccine candidates in healthy volunteers.
Merck to buy cancer drug developer ArQule for $2.7B in cash
The offer of $20 per share for ArQule is more than double its closing price on Friday.